Literature DB >> 8842495

Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls.

J Rak1, R S Kerbel.   

Abstract

Angiogenesis is essential for progressive solid tumor growth and thus constitutes a very promising therapeutic target. Recent developments in understanding of the molecular mechanisms involved in tumor blood vessel formation provides a rational basis for anti-angiogenic drug development, especially of more selective and effective agents. However, for the very same reason, it is time to think more critically about some of the potential pitfalls and difficulties associated with this treatment strategy and of research needed to define realistic expectations in this area.

Entities:  

Mesh：

Year:  1996        PMID： 8842495     DOI： 10.1007/bf00437476

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  37 in total

1.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

2.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells.

Authors:  E G Van Meir; P J Polverini; V R Chazin; H J Su Huang; N de Tribolet; W K Cavenee
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

3.  Angiogenesis and breast cancer.

Authors:  J Folkman
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

Review 4.  Barriers to drug delivery in solid tumors.

Authors:  R K Jain
Journal:  Sci Am       Date:  1994-07       Impact factor: 2.142

5.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

Authors:  D Mukhopadhyay; L Tsiokas; X M Zhou; D Foster; J S Brugge; V P Sukhatme
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

6.  Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells.

Authors:  S Grugel; G Finkenzeller; K Weindel; B Barleon; D Marmé
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.

Authors:  T G Graeber; C Osmanian; T Jacks; D E Housman; C J Koch; S W Lowe; A J Giaccia
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

9.  Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis.

Authors:  G Christofori; P Naik; D Hanahan
Journal:  Mol Endocrinol       Date:  1995-12

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728
View more
  12 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis.

Authors:  J Rak; Y Mitsuhashi; C Sheehan; J K Krestow; V A Florenes; J Filmus; R S Kerbel
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Authors:  Yong-Feng Yu; Zhi-Wei Chen; Zi-Ming Li; Zong-Hai Li; Shun Lu
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

4.  Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.

Authors:  M J Hendrix; E A Seftor; P S Meltzer; L M Gardner; A R Hess; D A Kirschmann; G C Schatteman; R E Seftor
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase.

Authors:  Madesh Belakavadi; Bharathi P Salimath
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

6.  Heterogeneous vascular dependence of tumor cell populations.

Authors:  J L Yu; J W Rak; P Carmeliet; A Nagy; R S Kerbel; B L Coomber
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

7.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

Authors:  L E Benjamin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 8.  The rationale and future potential of angiogenesis inhibitors in neoplasia.

Authors:  G Gasparini
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 9.  Angiogenesis-inhibitors for metastatic thyroid cancer.

Authors:  Aihua Tan; Ning Xia; Feng Gao; Zengnan Mo; Yunfei Cao
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

10.  Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model.

Authors:  L Possati; D Campioni; F Sola; L Leone; L Ferrante; C Trabanelli; M Ciomei; M Montesi; R Rocchetti; S Talevi; S Bompadre; A Caputo; G Barbanti-Brodano; A Corallini
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.